Polyomaviruses KI and WU in Immuno-compromised Patients with Respiratory Disease

Thomas Mourez, Anne Bergeron, Patricia Ribaud, Catherine Scieux, Régis Peffault de Latour, Abdellatif Tazi, Gérard Socié, François Simon, and Jérôme LeGoff

Polyomaviruses KI (KIPyV) and WU (WUPyV) were recently identified, mainly in respiratory specimens from children. Among 200 patients with respiratory disorders admitted to Saint Louis Hospital, Paris, France, KIPyV was detected in 8% and WUPyV in 1%. KIPyV was significantly more frequent among human stem cell transplant patients (17.8% vs. 5.1%; p = 0.01).

Recently, 2 new, distinct polyomaviruses (PyVs), KI (KIPyV) and WU (WUPyV), were identified in respiratory specimens, mainly from children <5 years of age with respiratory tract infections. The first retrospective studies of respiratory specimens in Sweden and Australia showed a KIPyV prevalence of 1% and 2.5%, respectively (1,2). Studies conducted in Australia and the United States showed a WUPyV prevalence in respiratory specimens of 3% and 0.7%, respectively (3). Further studies conducted in Canada and South Korea have shown similar frequencies (4,5). In this study, we examined the prevalence of KIPyV and WUPyV in immunocompromised patients with suspected respiratory tract infections.

The Study

From January through June 2007, 265 respiratory samples were received in the laboratory of Saint Louis Hospital, Paris: 154 nasal aspirates (NA) and 111 bronchoalveolar lavage (BAL) specimens collected from 200 patients with suspected upper or lower respiratory tract infections. This hospital specializes in the management of immunocompromised patients. Respiratory samples were collected for the diagnosis of acute respiratory illness; 89% of samples were from immunocompromised patients. Their median age was 46 years (range 3.6–85.3 years). Given the observational nature of the study, French law did not require ethical approval or informed consent.

The specimens were routinely tested for influenza A and B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, and 3 by immunofluorescence assay (Imagén; DakoCytomation, Trappes, France). Specimens positive for KIPyV or WUPyV were tested for adenoviruses; human bocavirus; human rhinoviruses; human metapneumovirus; human coronaviruses OC43, 229E, NL63, HKU1; and human PyVs BK and JC by using PCR methods (6–11). Total nucleic acid was extracted from 200 μL of NA, BAL, or stool specimens by using the EasyMag System (bioMérieux, Marcy l’Etoile, France). KIPyV was detected with an in-house real-time PCR assay targeting the VP1 gene. The primers and hydrolysis probe were designed by using Primer Express 3.0 software (Applied Biosystems, Foster City, CA, USA). The final reaction volume was 25 μL and contained 12.5 pmol of SLKI-VP1s (5′-GGAAATACAGCTGCTCAGGAT-3′) and SLKI-VP1as (5′-CTTTGTATACTTGACCGCTTTCC-3′), 6.25 pmol of corresponding probe SLKI-VP1PR (5′-6FAM-CGTGACCCACCCCTCATTACTCGTGC-TAMRA-3′), 12.5 μL of TaqMan Universal Master Mix (Applied Biosystems), and 5 μL of DNA extract. The reaction was run on a 7500 Real-Time PCR System (Applied Biosystems). The specificity of positive specimens was confirmed by using PCR and nested PCR with primers POLVP1–39F/POLVP1–363R and POLVP1–118F/POLVP1–324R, as described (1). The PCR products were then sequenced and compared with the previously described sequences from Sweden and Australia (GenBank accession nos. EF127906, EF127907, EF127908, EF520287, EF520288, and EF520289). WUPyV was detected by PCR as described (3). PCR products with the expected molecular weights were sequenced by using primers AG0044 and AG0045 and compared to published sequences (GenBank accession nos. EF444550, EF444551, EF444552, EF444553, and EF444554) (3).

KIPyV was detected in 17 (6.5%) of the 265 respiratory samples and in 16 (8.0%) of the 200 patients. All cases were confirmed by a nested PCR targeting another region of the VP1 gene. Twelve of the 17 PCR products were successfully sequenced, and all shared 100% homology with published sequences. WUPyV was detected in only 2 patients (1.0%). Genome sequencing showed 98% homology with reported WUPyV sequences.

Six KIPyV-positive patients (37.5%) had co-infections with other respiratory viruses, and 2 of them (12.5%) had a pulmonary bacterial infection (online Appendix Table, available from www.cdc.gov/EID/content/15/1/107-appT.htm). One WUPyV-infected patient who exhibited acute respiratory failure had concomitant pneumonia caused by Pseudomonas aeruginosa infection. None of the 15 patients who were positive for KIPyV or WUPyV and tested for fungi had respiratory or blood samples positive for Aspergillus spp.

Author affiliation: Hôpital Saint Louis, Paris, France

DOI: 10.3201/1501.080758
The clinical characteristics of the patients with KIPyV or WUPyV infection and their general outcome during 2007 are given in the online Appendix Table. All but 3 had well-identified systemic immunosuppression. However, all had severe coexisting conditions. All KIPyV- and WUPyV-positive patients had acute respiratory disorders.

Eight KIPyV-positive patients had received allogeneic stem cell transplants; 5 of them had exhibited profound neutropenia in the 2 weeks before the respiratory sample was found to be positive. The detection of KIPyV was significantly more frequent among hematopoietic stem cell transplant (HSCT) recipients than among other patients (17.8% [8/45] vs. 5.1% [8/155], p = 0.01) (Table). Lung or sinus imaging was assessed by computed tomography scan for 12 KIPyV-positive patients. Lung parenchyma abnormalities were noted in 9 patients, and sinusitis was diagnosed for 2 patients.

Taking into consideration both the frequency of digestive symptoms in our patients and the former published detection of KIPyV in a stool sample, we looked for KIPyV infection in the available stool samples while the respiratory samples were being assessed for KIPyV (J). Strikingly, 3 of 4 samples tested were positive for KIPyV (with cycle threshold values of 35.0, 38.3, and 40.3). All were collected from HSCT recipients. In addition, 1 HSCT patient who experienced diarrhea demonstrated persistent excretion of KIPyV in 9 consecutive stool specimens collected between June and the end of November 2007 (data not shown).

Conclusions

This study shows the prevalence of KIPyV and WUPyV among immunocompromised patients with respiratory disorders. Previously, these 2 viruses had been observed mainly in young children (J–3). Of the few adult patients with KIPyV or WUPyV infection mentioned in these studies, most were immunocompromised (3,12).

Considering the seemingly higher prevalence of KIPyV in our population (8%), immunocompromised patients may be more susceptible to this PyV, as they are to JC and BK viruses (13–15). Results from previous reports suggest a similar frequency of both KIPyV and WUPyV infections being found in respiratory specimens, ranging from 1% to 3%. In contrast, in our series, we found a likely difference between the prevalence of KIPyV (8%) and WUPyV (1%), which suggests that the replication or reactivation of the 2 viruses in the respiratory tract may differ between immunocompromised and immunocompetent patients. However, this difference requires further investigation, in particular, by using similar real-time PCR assays. Notably, a significantly higher prevalence of KIPyV infection was found among HSCT patients, which suggests that a profound T-cell deficiency may be a factor in facilitating KIPyV replication.

As reported in other populations, our patients who yielded positive specimens for KIPyV or WUPyV had conditions ranging from a common cold to acute respiratory distress that required invasive ventilation. Respiratory co-infections, observed in other studies, had likely accounted for at least some clinical features. In the 7 of our patients in whom KIPyV was the sole pathogen detected in the respiratory tract, despite comprehensive screening for viruses, bacteria, parasites, and fungi, clinical and radiographic patterns were varied. Some of the patients had only upper respiratory tract infections, notably sinusitis, whereas others had lung parenchyma abnormalities as defined by computed tomographic scan imaging. However, due to the retrospective nature of the study, and therefore the lack of a control group of immunocompromised patients without respiratory symptoms, the association of KIPyV infection with the occurrence of respiratory disease cannot be stated definitively.

In conclusion, the seemingly higher frequency of KIPyV shedding in immunocompromised patients (as observed with other PyVs) and the detection of KIPyV as a single pathogen in respiratory disease (e.g., as cytomegalovirus recurrence can lead to pneumonia in immunocompromised patients) together support a reactivation hypothesis. Nevertheless, a reinfection hypothesis cannot be excluded due to immunocompromised patients’ increased risk of acquiring viral infection from exogenous sources.

Controlled prospective studies of KIPyV shedding before and during immunosuppression will help determine the pathogenic role of this virus. The clinical implication of KIPyV detection in stools and the mechanisms underlying the concomitant presence in gastrointestinal and respiratory tracts also deserve further analysis.

Acknowledgments

We thank F. Freymuth, P. Lebon, and A. Vabret for advice and technical assistance and for providing positive virus controls.

Dr Mourez is a virologist in the Laboratory of Microbiology, Saint Louis University Hospital, Paris. His research interests include the development of tests for the diagnosis of emerging respiratory viruses and the study of the circulation and molecular analysis of human respiratory viruses in pediatric and immunocompromised patients.
Polyomaviruses in Immunocompromised Patients

References


Address for correspondence: Jérôme LeGoff, Laboratoire de Microbiologie, Hôpital Saint-Louis 1, Ave Claude Vellefaux 75010 Paris, France; email: jerome.le-goff@sls.aphp.fr

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.
### Appendix Table. Clinical characteristics and outcome of patients with KI or WU polyomavirus identified during the study*

<table>
<thead>
<tr>
<th>Sample no.</th>
<th>Age/y/sex</th>
<th>Date sample collected</th>
<th>Sample type</th>
<th>Ct value</th>
<th>Type of transplant/date</th>
<th>Underlying disease</th>
<th>Neutropenia in the past 2 weeks‡</th>
<th>Immunosuppressive treatment</th>
<th>Respiratory symptoms</th>
<th>Systemic symptoms</th>
<th>Digestive symptoms</th>
<th>Lung CT scan/sinus CT scan</th>
<th>Respiratory co-infections</th>
<th>Outcome of acute respiratory event</th>
<th>General outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>SL2-39</td>
<td>29/F</td>
<td>2007 Jan 26</td>
<td>BAL</td>
<td>35.9</td>
<td>None</td>
<td>Unclassified immune deficiency ALL</td>
<td>No</td>
<td>No</td>
<td>Cough, dyspnea, Epistaxis</td>
<td>Fever, myalgia</td>
<td>Fever</td>
<td>None</td>
<td>Bibrasal alveolar opacities/ND BD/bilateral maxillary sinusitis</td>
<td>Haemophilius influenzae</td>
<td>None</td>
</tr>
<tr>
<td>SL2-47</td>
<td>27/F</td>
<td>2007 Jan 27</td>
<td>NPA</td>
<td>37.3</td>
<td>Unrelated bone marrow/2007 Jan 26</td>
<td>Yes</td>
<td>Methotrexate Cyclosporine</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cured</td>
<td>Alive 2007 Sep 05</td>
</tr>
<tr>
<td>SL2-78</td>
<td>14/M</td>
<td>2007 Feb 5</td>
<td>NPA</td>
<td>39.4</td>
<td>T-cell ALL</td>
<td>Genoidentical bone marrow/2007 Feb 15</td>
<td>Yes</td>
<td>Cyclosporine</td>
<td>Cough, hypoxemia</td>
<td>Fever</td>
<td>None</td>
<td>None</td>
<td>Diffuse centrolobular micronodules/ND</td>
<td>MRV, MPV</td>
<td>None</td>
</tr>
<tr>
<td>SL2-95</td>
<td>73/F</td>
<td>2007 Feb 13</td>
<td>NPA</td>
<td>37.0</td>
<td>Chronic cardiac failure</td>
<td>None</td>
<td>No</td>
<td>None</td>
<td>Cough, dyspnea, hypoxemia</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Diffuse right ground glass opacities/ND</td>
<td>Cured 2007 Oct 11</td>
</tr>
<tr>
<td>SL2-33</td>
<td>39/M</td>
<td>2007 Feb 8</td>
<td>NPA</td>
<td>35.4</td>
<td>Chronic EBV-related lymphoid proliferation</td>
<td>None</td>
<td>Yes</td>
<td>Methotrexate Cyclosporine</td>
<td>Cough, shivers, Diaphragm, abdominal pain</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Normal/bilateral maxillary sinusitis</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>SL2-58</td>
<td>36/M</td>
<td>2007 Mar 13</td>
<td>NPA</td>
<td>21.5</td>
<td>ALL, Grade 4 GVHD</td>
<td>Genoidentical bone marrow/2008 Feb 8</td>
<td>Cough, sputum, rhinorrhea, pharyngitis</td>
<td>Prednisone (1.5 mg/kg/d)</td>
<td>Fever, shivers</td>
<td>Diaphragm, abdominal pain</td>
<td>None</td>
<td>None</td>
<td>NA</td>
<td>Died 2007 May 25#</td>
<td></td>
</tr>
<tr>
<td>SL2-78</td>
<td>72/M</td>
<td>2007 Mar 16</td>
<td>NPA</td>
<td>35.7</td>
<td>Chronic renal insufficiency, bronchiectasis</td>
<td>Prednisone (0.5 mg/kg/d)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cured 2007 Jul 17</td>
<td></td>
</tr>
<tr>
<td>SL2-80</td>
<td>72/F</td>
<td>2007 Mar 16</td>
<td>NPA</td>
<td>37.0</td>
<td>Severe respiratory insufficiency</td>
<td>None</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cured 2007 Sep 11</td>
<td></td>
</tr>
<tr>
<td>SL2-91</td>
<td>59/M</td>
<td>2007 Mar 22</td>
<td>NPA</td>
<td>34.0</td>
<td>None</td>
<td>None</td>
<td>Yes</td>
<td>Prednisone (0.75 mg/kg/d)</td>
<td>Fever, shivers</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cured 2007 Oct 10</td>
<td></td>
</tr>
<tr>
<td>SL2-92</td>
<td>28/F</td>
<td>2007 Apr 17</td>
<td>BAL</td>
<td>38.1</td>
<td>Aplastic anemia, dyskeratosis</td>
<td>Unrelated cord blood/2007 Feb 13</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cured 2007 Sep 19</td>
<td></td>
</tr>
<tr>
<td>SL2-93</td>
<td>42/M</td>
<td>2007 Jun 5</td>
<td>NPA</td>
<td>29.9</td>
<td>Systemic lupus erythematosus AML, chronic extensive GVHD</td>
<td>Unrelated bone marrow/2007 Jan 18</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cured 2007 Oct 19</td>
<td></td>
</tr>
</tbody>
</table>

*Sample numbers are assigned for identification purposes only.

**Sample types: BAL = bronchoalveolar lavage, NPA = nasopharyngeal aspirate.

†Underlying disease includes immune deficiency, acute leukemia, lymphoma, aplastic anemia, immunodeficiency, GVHD, systemic lupus erythematosus, and chronic renal insufficiency.

‡Neutropenia is defined as an absolute neutrophil count of less than 500 cells/μL.

§Respiratory co-infections include Haemophilus influenzae, Mycoplasma pneumoniae, and respiratory syncytial virus.

¶Outcome of acute respiratory event includes cured, progression, and death.

#General outcome includes alive, lost to follow-up, died, and alive with disease.
<table>
<thead>
<tr>
<th>SL4-94</th>
<th>17/M</th>
<th>2007 Jun 5</th>
<th>NPA</th>
<th>25.6</th>
<th>T-cell ALL</th>
<th>2 unrelated blood cords/ 2007 May 3</th>
<th>Yes</th>
<th>Prednisone (1 mg/kg/d)</th>
<th>Dyspnea</th>
<th>None</th>
<th>None §</th>
<th>Diffuse centrolobular nodules/ND</th>
<th>PIV</th>
<th>Cured</th>
<th>Alive 2007 Nov 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>WU polyomavirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SL4-89</td>
<td>46/M</td>
<td>2007 Jun 2</td>
<td>NPA</td>
<td></td>
<td>T-cell lymphoma</td>
<td>None</td>
<td>No</td>
<td>Cough, dyspnea</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Diffuse alveolar opacities and nodules/ND</td>
<td>None</td>
<td>Progression of lung lymphoma</td>
<td>Cured</td>
</tr>
<tr>
<td>SL4-100</td>
<td>44/F</td>
<td>2007 Jun 11</td>
<td>BAL</td>
<td></td>
<td>AML</td>
<td>None</td>
<td>No</td>
<td>NA (MV)</td>
<td>Fever</td>
<td>None</td>
<td>None</td>
<td>ND (bilateral opacities on chest radiograph)/ND</td>
<td>Pseudomonas aeruginosa</td>
<td>Cured</td>
<td>Alive 2007 Sep 2</td>
</tr>
</tbody>
</table>

*Ct, cycle threshold; CT, computed tomography; BAL, bronchoalveolar lavage; ND, not done; NPA, nasopharyngeal aspirate; ALL, acute lymphoblastic leukemia; hRV, human rhinovirus; HCoV, human coronavirus; hMPV, human metapneumovirus; EBV, Epstein-Barr virus; GVHD, graft versus host disease; IFA, influenza virus A; JCV, JC polyomavirus; BKV, BK polyomavirus; AML, acute myeloblastic leukemia; PIV, parainfluenza virus; NA, not applicable; MV, mechanical ventilation; †WBC < 0.5 × 10⁹/L.‡Patients with KIV positive stools §Death due to GVHD, aspergillosis, and multiple organ failure.¶Invasive pulmonary aspergillosis diagnosed 2007 Apr 4; former nodules on CT scan had resolved while new micronodules appeared in URL. #Due to aspergillosis and transplant rejection. **No new abnormality compared with known lung disease.